Oncology drives Chugai's underlying growth
This article was originally published in Scrip
Executive Summary
Chugaisaw its consolidated net profit for the nine months to September 30th remain static at ¥30.1 billion ($297.8 million), hit by sharply lower sales of Tamiflu (oseltamivir) and higher postmarketing surveillance (PMS) costs.